Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Divarasib |
Synonyms | |
Therapy Description |
GDC-6036 is a selective inhibitor of KRAS G12C that blocks downstream signaling, and may lead to anti-tumor activity (Annals of Oncology (2022) 33 (suppl_7): S197-S224). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Divarasib | GDC-6036|GDC6036|GDC 6036 | KRAS G12C inhibitor 32 | Divarasib (GDC-6036) is a selective inhibitor of KRAS G12C that blocks downstream signaling, and may lead to anti-tumor activity (PMID: 37611121). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04449874 | Phase I | Atezolizumab + Divarasib Bevacizumab + Divarasib Cetuximab + Divarasib Divarasib + Erlotinib Divarasib | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | Recruiting | USA | ITA | GBR | ESP | CAN | BEL | AUS | 11 |